Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Retained Earnings of -$24000.0 for Q1 2026, down 100.0% on a QoQ basis from $685.0 million in Q4 2025, and up 4.0% year-over-year from -$23076.9 in Q1 2025.
Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Retained Earnings history runs 7 years deep, the most recent figure standing at -$24000.0 for Q1 2026.
- Quarterly Retained Earnings rose 4.0% year-over-year to -$24000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24000.0 (up 4.0% YoY) and the FY2025 annual result came in at $685.0 million, up 6.66% from the prior year.
- Retained Earnings was -$24000.0 for Q1 2026 at Xeris Biopharma Holdings, down from $685.0 million in the prior quarter.
- Across five years, Retained Earnings topped out at $685.0 million in Q4 2025 and bottomed at -$683.0 million in Q2 2025.
- A 5-year average of -$135.0 million and a median of -$52000.0 in 2022 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 221.84% — and 2025, when it sank 2203125.81%.
- Xeris Biopharma Holdings' Retained Earnings stood at -$554.8 million in 2022, then decreased by 11.22% to -$617.0 million in 2023, then jumped by 204.09% to $642.3 million in 2024, then grew by 6.66% to $685.0 million in 2025, then slumped by 100.0% to -$24000.0 in 2026.
- Business Quant data shows XERS's Retained Earnings at -$24000.0 in Q1 2026, $685.0 million in Q4 2025, and -$682.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | 37.04 Bn |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 28.20 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn | 1.11 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 4.54 Bn |
| 5 | United Therapeutics | 23.04 Bn | 20.89 Bn | 648.10 Mn | 8.83 Bn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | -413.76 Mn |
| 7 | Viatris | 20.40 Bn | 18.60 Bn | 1.16 Bn | 18.66 Bn |
| 8 | Neurocrine Biosciences | 17.80 Bn | 16.49 Bn | 800.70 Mn | 589.60 Mn |
| 9 | Elanco Animal Health | 12.60 Bn | 12.17 Bn | 785.00 Mn | -2.13 Bn |
| 10 | Xeris Biopharma Holdings | 1.42 Bn | 1.31 Bn | 72.55 Mn | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24,000.00 |
| Dec 31, 2025 | 685.00 Mn |
| Sep 30, 2025 | -682.39 Mn |
| Jun 30, 2025 | -683.00 Mn |
| Mar 31, 2025 | -25,000.00 |
| Dec 31, 2024 | 642.26 Mn |
| Sep 30, 2024 | 638.43 Mn |
| Jun 30, 2024 | -31,000.00 |
| Mar 31, 2024 | -636.01 Mn |
| Dec 31, 2023 | -617.03 Mn |
| Sep 30, 2023 | -603.64 Mn |
| Jun 30, 2023 | -591.45 Mn |
| Mar 31, 2023 | 601.67 Mn |
| Dec 31, 2022 | -554.77 Mn |
| Sep 30, 2022 | -37,000.00 |
| Jun 30, 2022 | -52,000.00 |
| Mar 31, 2022 | -493.80 Mn |
| Dec 31, 2021 | -460.11 Mn |
| Sep 30, 2021 | -409.30 Mn |
| Dec 31, 2020 | 6,000.00 |